Concepedia

Rafael E. Curiel

RE

15

Publications

882

Citations

13

H-Index

1993

Active since

Affiliations

Eli Lilly (United States)(Current)

Frederick National Laboratory for Cancer Research

University Medical Center New Orleans

National Cancer Institute

Louisiana State University

Rafael E. Curiel is an author at Eli Lilly (United States) specializing in medicine, radiation oncology, and oncology.

ORCID

Top concepts

Publications per year

1993–2009

15

Publications

15

Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium

Christopher J. Sweeney, Bruce J. Roth, Fairooz F. Kabbinavar et al. · Journal of Clinical Oncology · 2006 · 245 citations

Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma

Premal H. Patel, P. Senico, Rafael E. Curiel et al. · Clinical Genitourinary Cancer · 2009 · 167 citations

, , +6

Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer

Ralph Zinner, Frank V. Fossella, Gregory W. Gladish et al. · Cancer · 2005 · 88 citations · Full text

Role of a STAT Binding Site in the Regulation of the Human Perforin Promoter

Cheng‐Rong Yu, John R. Ortaldo, Rafael E. Curiel et al. · The Journal of Immunology · 1999 · 76 citations · Full text

, , +19

IL-4 synergistically enhances both IL-2– and IL-12–induced IFN-γ expression in murine NK cells

Jay H. Bream, Rafael E. Curiel, Cheng‐Rong Yu et al. · Blood · 2003 · 52 citations · Full text

Rows per page

1–5 of 15